International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. The multifaceted impact of circadian disruption on cancer risk: a systematic review of insights and economic implications.Journal of the National Cancer Center · 2025
   Review
2. Efficacy of complementary and integrative medicine on health-related quality of life in cancer patients: a systematic review and meta-analysis.Cancer management and research · 2019
   Review
3. Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.Clinics (Sao Paulo, Brazil) · 2018
   Review
4. Targeted therapies for renal cell carcinoma.Nature reviews. Nephrology · 2017
   Review
5. Evaluating Frameworks That Provide Value Measures for Health Care Interventions.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017
   Article
6. New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment?Journal of global oncology · 2017
   Article
7. Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden.MDM policy & practice
   Article

Corrections and comments

• Comment on
  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.2015

Authors and funding

11 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as